Telomeres as targets for anticancer therapies

Introduction: The limitless replicative potential of cancer cells relies on telomere integrity (which is guaranteed by a complex interaction between several specialized proteins and telomeric DNA) and the activation of specific mechanisms for telomere length maintenance. Two mechanisms are currently known in human cancer, namely telomerase activity and the alternative lengthening of telomere pathway. Expert opinion: In this review, we summarize the available data concerning the therapeutic strategies proposed thus far and the current challenges posed for the development of innovative telomere-based therapeutic approaches with broad-spectrum anticancer activity and for their translation into the clinical setting. Areas covered: Due to their essential role in tumor cell proliferation, telomere maintenance mechanisms have become extremely attractive targets for the development of new anticancer interventions. Although numerous efforts have been made to identify specific approaches to interfere with telomere maintenance mechanisms in human cancers, the only molecule currently tested in clinical trials is the oligonucleotide GRN163L. However, a growing body of evidence suggests that interfering with telomeres, through the direct targeting of telomeric G-quadruplex structures, may be a valuable antitumor therapeutic strategy, independent of the specific telomere maintenance mechanism operating in the tumor.

[1]  A. Jeffreys,et al.  Activation of the ALT pathway for telomere maintenance can affect other sequences in the human genome. , 2005, Human molecular genetics.

[2]  E. Gilson,et al.  How telomeres are replicated , 2007, Nature Reviews Molecular Cell Biology.

[3]  J. Royds,et al.  Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme , 2003, The Lancet.

[4]  J. Mergny,et al.  Cell senescence and telomere shortening induced by a new series of specific G-quadruplex DNA ligands , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[5]  J. Testa,et al.  Whole-genome profiling in liposarcomas reveals genetic alterations common to specific telomere maintenance mechanisms. , 2007, Cancer research.

[6]  M. Palumbo,et al.  Quinone methides tethered to naphthalene diimides as selective G-quadruplex alkylating agents. , 2009, Journal of the American Chemical Society.

[7]  M. Searle,et al.  Drug recognition and stabilisation of the parallel-stranded DNA quadruplex d(TTAGGGT)4 containing the human telomeric repeat. , 2003, Journal of Molecular Biology.

[8]  B. Gatto,et al.  Nucleic acid aptamers based on the G-quadruplex structure: therapeutic and diagnostic potential. , 2009, Current medicinal chemistry.

[9]  E. Gilson,et al.  Stabilization of quadruplex DNA perturbs telomere replication leading to the activation of an ATR-dependent ATM signaling pathway , 2009, Nucleic acids research.

[10]  M. Ladanyi,et al.  Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. , 2003, Cancer research.

[11]  M. Blasco,et al.  Telomere length, stem cells and aging. , 2007, Nature chemical biology.

[12]  E. Blackburn,et al.  Rapid Inhibition of Cancer Cell Growth Induced by Lentiviral Delivery and Expression of Mutant-Template Telomerase RNA and Anti-telomerase Short-Interfering RNA , 2004, Cancer Research.

[13]  J. Groden,et al.  Unwinding protein complexes in ALTernative telomere maintenance , 2009, Journal of cellular biochemistry.

[14]  J. Shay,et al.  The effects of telomerase inhibition on prostate tumor‐initiating cells , 2010, International journal of cancer.

[15]  M. Stevens,et al.  Potent inhibition of telomerase by small-molecule pentacyclic acridines capable of interacting with G-quadruplexes. , 2001, Molecular pharmacology.

[16]  Jean-Louis Mergny,et al.  Targeting telomeres and telomerase. , 2008, Biochimie.

[17]  Yuliang Wu,et al.  G‐quadruplex nucleic acids and human disease , 2010, The FEBS journal.

[18]  Amy Y. M. Au,et al.  DNA C-circles are specific and quantifiable markers of alternative-lengthening-of-telomeres activity , 2009, Nature Biotechnology.

[19]  J. Mergny,et al.  Telomerase downregulation induced by the G-quadruplex ligand 12459 in A549 cells is mediated by hTERT RNA alternative splicing. , 2004, Nucleic acids research.

[20]  M. Daidone,et al.  Multiple Mechanisms of Telomere Maintenance Exist and Differentially Affect Clinical Outcome in Diffuse Malignant Peritoneal Mesothelioma , 2008, Clinical Cancer Research.

[21]  P. Baumann,et al.  G-Quadruplexes: From Guanine Gels to Chemotherapeutics , 2011, Molecular biotechnology.

[22]  Lin Ma,et al.  Synthesis and evaluation of quindoline derivatives as G-quadruplex inducing and stabilizing ligands and potential inhibitors of telomerase. , 2005, Journal of medicinal chemistry.

[23]  G. Guy,et al.  BNIP-Sα induces cell rounding and apoptosis by displacing p50RhoGAP and facilitating RhoA activation via its unique motifs in the BNIP-2 and Cdc42GAP homology domain , 2006, Oncogene.

[24]  G. Wakabayashi,et al.  Downregulation of miR‐138 is associated with overexpression of human telomerase reverse transcriptase protein in human anaplastic thyroid carcinoma cell lines , 2008, Cancer science.

[25]  T. Bryan,et al.  Interrogation of G-quadruplex-protein interactions. , 2007, Methods.

[26]  K. Shin‐ya,et al.  Activity of a novel G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095), against human leukemia cells: involvement of ATM-dependent DNA damage response pathways , 2003, Oncogene.

[27]  C. Harley,et al.  Imetelstat (GRN163L)--telomerase-based cancer therapy. , 2010, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[28]  N. Zaffaroni,et al.  Targeting the telosome: therapeutic implications. , 2009, Biochimica et biophysica acta.

[29]  U. Martens,et al.  Telomerase inhibition and telomere targeting in hematopoietic cancer cell lines with small non-nucleosidic synthetic compounds (BIBR1532). , 2007, Methods in molecular biology.

[30]  J. Shay,et al.  Telomere biology in Metazoa , 2010, FEBS letters.

[31]  D. Fan,et al.  TRF2 promotes multidrug resistance in gastric cancer cells , 2006, Cancer biology & therapy.

[32]  H. Stein,et al.  [Telomerase as a tumor marker?]. , 1997, Verhandlungen der Deutschen Gesellschaft fur Pathologie.

[33]  F. Ishikawa,et al.  Alternative lengthening of telomeres pathway: recombination-mediated telomere maintenance mechanism in human cells. , 2011, Journal of biochemistry.

[34]  J. Mergny,et al.  Apoptosis related to telomere instability and cell cycle alterations in human glioma cells treated by new highly selective G-quadruplex ligands , 2005, Oncogene.

[35]  Stephen Neidle,et al.  A G-quadruplex telomere targeting agent produces p16-associated senescence and chromosomal fusions in human prostate cancer cells. , 2004, Molecular cancer therapeutics.

[36]  E. Gilson,et al.  G-Quadruplex Ligand RHPS4 Potentiates the Antitumor Activity of Camptothecins in Preclinical Models of Solid Tumors , 2008, Clinical Cancer Research.

[37]  J. Mergny,et al.  A G-quadruplex structure within the 5′-UTR of TRF2 mRNA represses translation in human cells , 2010, Nucleic acids research.

[38]  Stephen Neidle,et al.  Design, synthesis and evaluation of 4,5-di-substituted acridone ligands with high G-quadruplex affinity and selectivity, together with low toxicity to normal cells. , 2009, Bioorganic & medicinal chemistry letters.

[39]  Katrin Paeschke,et al.  Telomeres: Structures in need of unwinding , 2010, FEBS letters.

[40]  S. Stewart,et al.  The role of telomeres and telomerase in cancer research. , 2010, Cancer research.

[41]  Stephen Neidle,et al.  The G-quadruplex-interactive molecule BRACO-19 inhibits tumor growth, consistent with telomere targeting and interference with telomerase function. , 2005, Cancer research.

[42]  E. Blackburn,et al.  A low threshold level of expression of mutant-template telomerase RNA inhibits human tumor cell proliferation , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[43]  E. Gilson,et al.  PARP1 is activated at telomeres upon G4 stabilization: possible target for telomere-based therapy , 2010, Oncogene.

[44]  Xuedong Liu,et al.  Structural basis of selective ubiquitination of TRF1 by SCFFbx4. , 2010, Developmental cell.

[45]  J. Lingner,et al.  TERRA biogenesis, turnover and implications for function , 2010, FEBS letters.

[46]  E. Blackburn,et al.  ATM mediates cytotoxicity of a mutant telomerase RNA in human cancer cells. , 2008, Cancer research.

[47]  B. Dutrillaux,et al.  Preferential binding of a G-quadruplex ligand to human chromosome ends , 2005, Nucleic acids research.

[48]  F. Bollmann.  The many faces of telomerase: emerging extratelomeric effects , 2008, BioEssays : news and reviews in molecular, cellular and developmental biology.

[49]  N. Zaffaroni,et al.  Evidence for alternative lengthening of telomeres in liposarcomas in the absence of ALT‐associated PML bodies , 2008, International journal of cancer.

[50]  S. Neidle,et al.  Inhibition of human telomerase by a G-quadruplex-interactive compound. , 1997, Journal of medicinal chemistry.

[51]  P. Baumann,et al.  Human RAP1 inhibits non‐homologous end joining at telomeres , 2009, The EMBO journal.

[52]  K. Shin‐ya,et al.  The G-Quadruplex Ligand Telomestatin Impairs Binding of Topoisomerase IIIα to G-Quadruplex-Forming Oligonucleotides and Uncaps Telomeres in ALT Cells , 2009, PloS one.

[53]  T. de Lange.  How Telomeres Solve the End-Protection Problem , 2009, Science.

[54]  K. Anderson,et al.  Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma. , 2003, Molecular cancer therapeutics.

[55]  R. Reddel,et al.  Identification of candidate alternative lengthening of telomeres genes by methionine restriction and RNA interference , 2007, Oncogene.

[56]  Y-X Zeng,et al.  Inhibition of myc promoter and telomerase activity and induction of delayed apoptosis by SYUIQ-5, a novel G-quadruplex interactive agent in leukemia cells , 2007, Leukemia.

[57]  E. Skordalakes,et al.  Structural basis for telomerase catalytic subunit TERT binding to RNA template and telomeric DNA , 2010, Nature Structural &Molecular Biology.

[58]  J. Shay,et al.  Antiadhesive effects of GRN163L--an oligonucleotide N3'->P5' thio-phosphoramidate targeting telomerase. , 2007, Cancer research.

[59]  R. Deng,et al.  G-quadruplex ligand SYUIQ-5 induces autophagy by telomere damage and TRF2 delocalization in cancer cells , 2009, Molecular Cancer Therapeutics.

[60]  K. Shin‐ya,et al.  Disabling c-Myc in Childhood Medulloblastoma and Atypical Teratoid/Rhabdoid Tumor Cells by the Potent G-Quadruplex Interactive Agent S2T1-6OTD , 2010, Molecular Cancer Therapeutics.

[61]  R. Deng,et al.  Senescence and telomere shortening induced by novel potent G-quadruplex interactive agents, quindoline derivatives, in human cancer cell lines , 2006, Oncogene.

[62]  L. Hurley,et al.  Formation of a unique end-to-end stacked pair of G-quadruplexes in the hTERT core promoter with implications for inhibition of telomerase by G-quadruplex-interactive ligands. , 2009, Journal of the American Chemical Society.

[63]  Charles A Laughton,et al.  Pharmacodynamics of the G-Quadruplex-Stabilizing Telomerase Inhibitor 3,11-Difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate (RHPS4) in Vitro: Activity in Human Tumor Cells Correlates with Telomere Length and Can Be Enhanced, or Antagonized, with Cytotoxic Agents , 2005, Molecular Pharmacology.

[64]  S. Neidle,et al.  A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity. , 2002, Molecular pharmacology.

[65]  J. Shay,et al.  In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. , 2005, Cancer research.

[66]  S. Neidle,et al.  Tetrasubstituted naphthalene diimide ligands with selectivity for telomeric G-quadruplexes and cancer cells. , 2010, Bioorganic & medicinal chemistry letters.

[67]  Timothy D. Veenstra,et al.  A Human Telomerase Holoenzyme Protein Required for Cajal Body Localization and Telomere Synthesis , 2009, Science.

[68]  E. LaVoie,et al.  A G-quadruplex Stabilizer Induces M-phase Cell Cycle Arrest* , 2009, The Journal of Biological Chemistry.

[69]  P. Baumann,et al.  Apollo-taking the lead in telomere protection. , 2010, Molecular cell.

[70]  E. Maher,et al.  The Telomerase Antagonist, Imetelstat, Efficiently Targets Glioblastoma Tumor-Initiating Cells Leading to Decreased Proliferation and Tumor Growth , 2010, Clinical Cancer Research.

[71]  S. Neidle,et al.  C-11 diamino cryptolepine derivatives NSC748392, NSC748393, and NSC748394: anticancer profile and G-quadruplex stabilization. , 2010, Bioorganic & medicinal chemistry letters.

[72]  J. Postberg,et al.  Probing telomeric G-quadruplex DNA structures in cells with in vitro generated single-chain antibody fragments. , 2010, Methods in molecular biology.

[73]  Claudia Sissi,et al.  Remarkable interference with telomeric function by a G-quadruplex selective bisantrene regioisomer. , 2010, Biochemical pharmacology.

[74]  E. Blackburn.  Telomeres and telomerase: the means to the end (Nobel lecture). , 2010, Angewandte Chemie.

[75]  J. Shay,et al.  Telomerase therapeutics for cancer: challenges and new directions , 2006, Nature Reviews Drug Discovery.

[76]  Barbara Benassi,et al.  Biological Activity of the G-Quadruplex Ligand RHPS4 (3,11-Difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate) Is Associated with Telomere Capping Alteration , 2004, Molecular Pharmacology.

[77]  L. Siu,et al.  First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting , 2008, Journal of hematology & oncology.

[78]  R. Glasspool,et al.  Lack of telomerase gene expression in alternative lengthening of telomere cells is associated with chromatin remodeling of the hTR and hTERT gene promoters. , 2005, Cancer research.

[79]  Laura Johnson,et al.  Dietary Energy Density Affects Fat Mass in Early Adolescence and Is Not Modified by FTO Variants , 2009, PloS one.

[80]  R. Reddel,et al.  Alternative lengthening of telomeres: models, mechanisms and implications , 2010, Nature Reviews Genetics.

[81]  J. Fletcher,et al.  Targeting human gastrointestinal stromal tumor cells with a quadruplex-binding small molecule. , 2009, Journal of medicinal chemistry.

[82]  Haiyong Han,et al.  The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo. , 2002, Molecular cancer therapeutics.

[83]  L. Mariani,et al.  Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression. , 2006, Cancer research.

[84]  J. Harper,et al.  Telomeric TuRF1 wars. , 2010, Developmental cell.

[85]  Stephen Neidle,et al.  Human telomeric G‐quadruplex: The current status of telomeric G‐quadruplexes as therapeutic targets in human cancer , 2010, The FEBS journal.

[86]  S. Neidle,et al.  G-quadruplex compounds and cis-platin act synergistically to inhibit cancer cell growth in vitro and in vivo. , 2009, Biochemical pharmacology.

[87]  Carlo Leonetti,et al.  Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect. , 2007, The Journal of clinical investigation.

[88]  V. Brower.  Telomerase-based therapies emerging slowly. , 2010, Journal of the National Cancer Institute.

[89]  Sandy Chang,et al.  Telomere dysfunction and tumour suppression: the senescence connection , 2008, Nature Reviews Cancer.

[90]  E. Gilson,et al.  CST meets shelterin to keep telomeres in check. , 2010, Molecular cell.

[91]  C. Harris,et al.  POT1 and TRF2 Cooperate To Maintain Telomeric Integrity , 2005, Molecular and Cellular Biology.

[92]  K. Shin‐ya,et al.  Resistance to senescence induction and telomere shortening by a G-quadruplex ligand inhibitor of telomerase. , 2003, Cancer research.

[93]  E. Blackburn,et al.  Assembly of mutant-template telomerase RNA into catalytically active telomerase ribonucleoprotein that can act on telomeres is required for apoptosis and cell cycle arrest in human cancer cells. , 2006, Cancer research.

[94]  J. Shay,et al.  POT1 protects telomeres from a transient DNA damage response and determines how human chromosomes end , 2005, The EMBO journal.

[95]  R. Reddel,et al.  Disruption of Telomere Maintenance by Depletion of the MRE11/RAD50/NBS1 Complex in Cells That Use Alternative Lengthening of Telomeres* , 2007, Journal of Biological Chemistry.

[96]  R. Reddel,et al.  Assaying and investigating Alternative Lengthening of Telomeres activity in human cells and cancers , 2010, FEBS letters.

[97]  P. Lou,et al.  Detection of quadruplex DNA structures in human telomeres by a fluorescent carbazole derivative. , 2004, Analytical chemistry.

[98]  C. Laughton,et al.  The levels of telomere-binding proteins in human tumours and therapeutic implications. , 2009, European journal of cancer.